

Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma

YA Bochkov¹, KM Hanson¹, S Keles², RA Brockman-Schneider¹, NN Jarjour³ and JE Gern^{1,3}

Rhinovirus (RV) infections trigger asthma exacerbations. Genome-wide expression analysis of RV1A-infected primary bronchial epithelial cells from normal and asthmatic donors was performed to determine whether asthma is associated with a unique pattern of RV-induced gene expression. Virus replication rates were similar in cells from normal and asthmatic donors. Overall, RV downregulated 975 and upregulated 69 genes. Comparisons of transcriptional profiles generated from microarrays and confirmed by quantitative reverse transcription PCR and cluster analysis showed some up- and downregulated genes in asthma cells involved in immune responses (*IL1B*, *IL1F9*, *IL24*, and *IFI44*) and airway remodeling (*LOXL2*, *MMP10*, *FN1*). Notably, most of the asthma-related differences in RV-infected cells were also present in the cells before infection. These findings suggest that differences in RV-induced gene expression profiles of cells from normal and mild asthmatic subjects could affect the acute inflammatory response to RV, and subsequent airway repair and remodeling.

INTRODUCTION

Human rhinoviruses (RVs) cause the common cold and are frequently detected in asthma exacerbations. RV typically induces neutrophilic inflammation in the upper airways of both asthmatic and non-asthmatic patients; however, in asthmatics, these infections can lead to more severe lower respiratory symptoms and reductions in lung function. Interestingly, the severity of asthma symptoms may not be related to viral load, prolonged viral shedding, or to differences in proinflammatory cytokines in the upper airway secretions.^{1,2} Understanding the mechanisms provoking RV-induced airway inflammation in asthma, as well as the mechanisms linking RV infection to asthma exacerbations, may offer significant opportunities for improved disease management.

Rhinovirus infection of airway epithelial cells induces the production of a wide range of mediators involved in inflammatory and immune processes.^{3,4} Transcriptional profiling of differentiated cultures of human primary bronchial epithelial (PBE) cells from two normal subjects has shown that RV infection induces a number of genes in the interferon (IFN)- β -dependent pathway.⁵ Furthermore, cultured epithelial cells from the airways of subjects with asthma have been found to have deficient innate immune responses to RV16 infection, character-

ized by increased viral replication, impaired early induction of apoptosis, and reduced type I and type III IFN production.^{6,7} Collectively, these studies suggest that RV-induced airway disease could be due to asthma-related changes in gene expression in airway epithelium. The aim of this study is to compare RV-induced genome-wide gene expression profiles of cultured airway epithelial cells obtained from subjects with and without asthma to identify genes that may have a role in virus-induced asthma exacerbations.

RESULTS

RV1A infection of PBE cells and viral RNA quantification

Primary bronchial epithelial cells (samples 7–18) from six normal subjects and six subjects with asthma (Table 1) were inoculated with RV1A (MOI (multiplicity of infection) of 10 PFU (plaque-forming units) per cell); for one subject with asthma (sample 11), the RNA yield after infection was insufficient for further analysis. Total RNA isolated from adherent cells collected 16 h post-infection (p.i.) was analyzed using microarrays. Viral RNA was measured by quantitative reverse transcription (qRT)-PCR in growth media from the PBE cell cultures. We then repeated the process of infecting cells from these donors so that the results of the microarray experiments could be retested in separate experiments

¹Department of Pediatrics, University of Wisconsin, Madison, Wisconsin, USA. ²Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, USA. ³Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA. Correspondence: YA Bochkov (yabochkov@wisc.edu)

Received 1 December 2008; accepted 29 July 2009; published online 26 August 2009. doi:10.1038/mi.2009.109

Table 1 Characteristics of subjects with asthma and controls

Subject ^a	Asthma	Gender	Age (years)	PC ₂₀ (mg ml ⁻¹)	FEV1 % predicted	Reversibility (%)	Allergen skin test
1	No	F	20	20	110	3	–
2	No	F	21	20	113	1	–
3	No	F	20	20	83	4	–
4	Yes	F	19	0.3	69	36	+
5	Yes	F	22	1.0	103	16	+
6	Yes	M	21	2.5	91	12	+
7 ^b	No	M	24	20	86	7	–
8 ^b	No	F	19	20	99	3	–
9 ^b	No	M	21	20	99	5	–
10 ^b	Yes	F	22	1.0	73	12	+
11 ^c	Yes	M	25	2.2	80	16	+
12 ^b	Yes	M	25	0.3	82	4	+
13 ^b	No	F	41	20	91	5	–
14 ^b	No	F	24	20	106	6	–
15 ^b	No	M	37	20	110	1	–
16 ^b	Yes	F	32	0.5	63	23	+
17 ^b	Yes	M	35	4.6	90	7	+
18 ^b	Yes	F	28	2.5	72	17	+

F, female; FEV1, forced expiratory volume in 1 sec; M, male; PC₂₀, provocative concentration of methacholine causing a 20% fall in FEV1.

^aCells from subjects 1–6 were analyzed in preliminary experiments using HG Focus GeneChips; cells from subjects 7–18 were tested using HG U133 Plus 2.0 GeneChips.

^bSamples were used for quantitative PCR validation and viral RNA quantification in independent experiments.

^cSample was not analyzed by GeneChip because of the insufficient total RNA yield.

and using a different technology (qRT-PCR) to measure changes in host gene expression and viral RNA. Virus-induced cytopathic effect, as determined by light microscopy (**Figure 1a**), was similar in cells from normal and asthmatic subjects. In addition, there were no group-specific differences in the amount of viral RNA released into the media (including floating cells), in adherent cells, or in the total amount of RNA per well (sum of RNA in media and in the floating and adherent cells) (**Figure 1b**, $P>0.05$).

Gene expression changes in response to infection

To determine the transcriptional response of normal and asthmatic PBE cells to RV1A infection, we started by comparing genome-wide gene expression profiles in infected cells and mock-infected controls in each group. We identified a total of 1,317 probe sets corresponding to 1,044 known human genes with at least a twofold change in expression in RV-infected PBE cells vs. mock-infected control cells, in both groups. Combined lists of the 40 most highly up- and downregulated transcripts found in normal and asthmatic cells are shown in **Table 2**, and complete lists of genes are provided in **Supplementary Tables S1** and **S2** online.

The majority of affected genes were downregulated in infected cells compared with mock-infected control samples (**Figure 2a**). This finding is consistent with global host cell transcriptional shutoff due to RV-induced cleavages of multiple transcription factors and nuclear pore complex components.^{8,9} Virus infection decreased the expression of genes related to antiviral defense

(influenza virus NS1A-binding protein), apoptosis (TIA1 cytoxic granule-associated RNA-binding protein), and regulation of cell-cycle (discs, large homolog 1 (*Drosophila*); ubiquitin-like, containing PHD and RING finger domains; cyclin-dependent kinase inhibitor 2B) as well as multiple proteins participating in cell metabolism (**Table 2**).

Genes exhibiting an increase in expression (greater than or equal to twofold) included 53 genes found in normal samples and 54 genes in the asthma group that together comprise 69 unique genes (**Supplementary Table S1** online). Among the induced genes were those encoding chemoattractants for granulocytes, macrophages, and T lymphocytes (chemokine (C–X–C motif) ligand (CXCL) 1, 2, and 3; interleukin (IL) 8; and chemokine (C–C motif) ligand (CCL) 20), cytokines (colony-stimulating factors (CSF) 2 and 3; *IL1F9*; *IL6*; and *IL24*), decoy cytokine receptors (IL1 receptor, type II; IL1 receptor antagonist (*IL1RN*); IL13 receptor, α 2), and transcription factors and regulators, such as early growth response 1 (*EGR1*), FOS-like antigen 1 (*FOSL1*), nuclear factor-kappa B (NF κ B) inhibitors Z and A (NF κ BIZ and *NF κ BIA*), and zinc finger CCCH-type containing 12A (**Table 2**). Two cytokine genes (*IL1F9* and *IL24*) revealed more robust upregulation after RV infection in the asthma group. We also observed an increase in expression of antiviral response genes (2'-5'-oligoadenylate synthetase-like (*OASL*), IFN-induced protein 44 (*IFI44*), and *IL28A* (IFN, λ 2)) in normal cells and of regulators of smooth muscle tone (adrenergic receptor, β 2 (*ADRB2*) and endothelin 1 (*EDN1*)) in both groups.




Figure 1 Rhinovirus (RV)1A infection induces similar cytopathic effect and viral RNA yield in cells obtained from donors with asthma and normal donors. **(a)** Representative microphotographs (magnification $\times 100$) of primary bronchial epithelial (PBE) cells from one normal donor (no. 13) and one patient with asthma (no. 18) taken just after virus attachment period (left panel) and 16 h post-infection (p.i.) with medium alone (middle panel) or medium containing 10 plaque-forming units (PFU) per cell of RV1A (right panel). **(b)** Quantification of viral RNA in adherent cells and growth media (including floating cells) collected 16 h p.i. of PBE cell cultures. Media samples both after microarray and quantitative PCR validation experiments were summarized. Viral RNA for each graph was calculated from each well of a six-well plate. Horizontal bars indicate medians. HRV, human RV.

We then compared these gene expression changes with results from six additional PBE cell cultures (three normal donors and three donors with asthma, **Table 1**) that were similarly infected in preliminary studies and explored using the HG Focus chips (Affymetrix, Santa Clara, CA) with lower probe density ($>8,700$ probe sets). All of the probe sets from the smaller chip are also present in the higher-density HG U133 Plus 2.0 arrays to enable comparability. Although we observed some differences in magnitude of changes between two microarray data sets (**Table 2**), the overall core set of virus-induced genes was similar (**Supplementary Table S3** online).

Asthma-specific gene expression profiles in PBE cells

We next compared RV-induced responses in the asthma vs. normal groups. In general, patterns of gene expression were quite similar in the two groups, with a few notable exceptions. Direct comparisons of transcriptional profiles after infection identified nine genes with greater than or equal to twofold up- or down-regulation in the asthma group compared with normal controls (**Table 3**). Genes with higher expression in the asthma group included those with functions related to inflammation (*IL1F9*), tumor suppressor activity (*C15orf48*), and airway repair and remodeling (inhibin, β A (*INHBA*); lysyl oxidase-like 2 (*LOXL2*); and matrix metalloproteinase 10 (*MMP10*)). In contrast, *IFI44*,

an IFN response gene, and tumor suppressor gene, microsemionoprotein β (*MSMB*), revealed lower expression in the asthma group. Six of these genes were also differentially expressed in mock-infected cells from asthma patients (**Table 3**).

Using a less stringent 1.5-fold criterion for group-specific differences in gene expression, a total of 42 genes were identified, including 32 with higher expression and 10 with lower expression in infected cells from the asthma vs. normal groups. (**Supplementary Table S4** online). These genes separated the samples into four branches based on hierarchical clustering of gene expression patterns with or without viral infection (**Figure 2b**). Clusters of genes distinguished by this approach included those with higher expression in asthmatic cells after infection (Cluster I), those with higher expression in both mock-infected and RV-infected asthma samples (Cluster II), and those genes with increased expression in mock- or RV-infected cells from normal donors (Cluster III). Interestingly, one gene from this cluster (*MSMB*) revealed higher expression both at baseline (mock infection) and after RV infection in the samples from three normal female subjects.

Alternative hierarchical clustering of samples using gene expression ratios (fold differences) revealed groupings of up- and downregulated genes, but did not reveal differences related to asthma (**Supplementary Figure 1** online). These findings

Table 2 RV-induced changes in gene expression: combined asthma and normal groups

Gene symbol	Gene name	Biological function	Normal FD ^a	Asthma FD ^a
Upregulated genes				
<i>CXCL3</i>	Chemokine (C–X–C motif) ligand 3	Chemokine	12.2/36.7	12.6/5.6
<i>CXCL2</i>	Chemokine (C–X–C motif) ligand 2	Chemokine	6.7/9.4	7.3/6.6
<i>IL8</i>	Interleukin 8	Chemokine	5.7/20.7	5.7/4.4
<i>CSF3</i>	Colony-stimulating factor 3 (granulocyte)	Cytokine	5.4	7.2
<i>IL1R2</i>	Interleukin 1 receptor, type II	Cytokine receptor	5.1	7.5
<i>CXCL1</i>	Chemokine (C–X–C motif) ligand 1	Chemokine	4.7/6.2	4.1/3.9
<i>EGR1</i>	Early growth response 1	Transcription factor	4.6	4.4
<i>SERPINB2</i>	Serpin peptidase inhibitor, clade B (ovalbumin), member 2	Endopeptidase	4.4	5.3
<i>TNFAIP3</i>	Tumor necrosis factor, alpha-induced protein 3	Inhibitor of apoptosis	3.9/4.9	3.9/2.0
<i>CCL20</i>	Chemokine (C–C motif) ligand 20	Chemokine	3.8/5.7	4.5/3.8
<i>IL13RA2</i>	Interleukin 13 receptor, alpha 2	Cytokine receptor	3.7	4.7
<i>CSF2</i>	Colony-stimulating factor 2 (granulocyte–macrophage)	Cytokine	3.6/4.1	3.2
<i>IL1F9</i>	Interleukin 1 family, member 9	Cytokine	3.5	6.0
<i>SPRR2B</i>	Small proline-rich protein 2B	Structural molecule	3.1	4.5
<i>ZC3H12A</i>	Zinc finger CCCH-type containing 12A	Transcription regulator	3.1	3.2
<i>IL6</i>	Interleukin 6	Cytokine	2.9/5.6	3.7
<i>NFKBIZ</i>	Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta	Transcription regulator	2.8	3.2
1558048_x_at ^b	cDNA clone IMAGE:4523513	NA	2.7	3.1
<i>S100A3</i>	S100 calcium-binding protein A3	Calcium and zinc binding	2.7	2.6/2.0
<i>SOCS3</i>	Suppressor of cytokine signaling 3	JAK2 kinase inhibitor	2.7	3.3
Downregulated genes				
225123_at ^b	FLJ33813	NA	9.1	8.4
<i>IVNS1ABP</i>	Influenza virus NS1A-binding protein	Response to virus	8.6	8.3
<i>ITGB6</i>	Integrin, beta 6	Receptor for fibronectin	7.0	8.9
<i>DLG1</i>	Discs, large homolog 1 (<i>Drosophila</i>)	Cell-cycle regulation	5.7	5.4
<i>TIA1</i>	TIA1 cytotoxic granule-associated RNA-binding protein	Inductor of apoptosis	5.6	4.4
<i>FN1</i>	Fibronectin 1	ECM constituent	5.6	4.1
<i>SLITRK6</i>	SLIT and NTRK-like family, member 6	Membrane protein	5.4	4.2
<i>PCMTD1</i>	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1	Protein modification	5.3	5.2
<i>ACSL3</i>	Acyl-CoA synthetase long-chain family member 3	Lipid biosynthesis	5.2	4.3
<i>UHRF2</i>	Ubiquitin-like, containing PHD and RING finger domains, 2	Cell-cycle regulation	5.0	4.4
<i>CDKN2B</i>	Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	Cell-cycle regulation	5.0	4.5
<i>PLOD2</i>	Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2	Hydroxylation of lysyl residues in collagen	5.0	4.7
<i>FLRT2</i>	Fibronectin leucine-rich transmembrane protein 2	Cell adhesion and/or receptor signaling	4.9	5.2
<i>MAF</i>	v-maf Musculoaponeurotic fibrosarcoma oncogene homolog	Transcription factor	4.8	5.4
<i>GBP3</i>	Guanylate-binding protein 3	GTP binding	4.8	3.9
<i>SFRS12</i>	Splicing factor, arginine/serine-rich 12	Splicing factor	4.8	3.4
<i>KITLG</i>	KIT ligand	Ligand of the tyrosine-kinase receptor	4.8	3.6
<i>SMC4</i>	Structural maintenance of chromosomes 4	Chromosome organization	4.8	2.7
<i>TTC37</i>	Tetratricopeptide repeat domain 37	Binding	4.8	3.1
<i>SLC39A10</i>	Solute carrier family 39 (zinc transporter), member 10	Zinc ion transport	4.8	4.4

ECM, extracellular matrix; FD, fold difference (in expression); NA, not available; RV, rhinovirus.

^aCorresponding fold differences in expression (nominal $P < 0.05$) generated by HG Focus microarray using cells from six additional donors (three normal and three asthmatic) are indicated after "slash".

^bAffymetrix probe set ID is used when gene symbol is not available.

indicate that most of the asthma-related differences in human RV-induced patterns of gene expression were also present without infection.

Functional analysis of genes affected by RV infection

Functional analysis based on the Gene Ontology classifications (Database for Annotation, Visualization and Integrated Discovery (DAVID)) showed that most genes induced by RV infection of both asthma and normal samples were related to inflammatory responses. Interestingly, there were nine RV-induced genes (*CCL5*, prostaglandin-endoperoxide synthase 2 (*PTGS2*), superoxide dismutase 2, *CSF2*, tumor necrosis factor (*TNF*), *IL1RN*, *EDN1*, *ADRB2*, and suppressor of cytokine signaling 1 (*SOCS1*)) that have been associated with asthma in genetic studies (Genetic Association Database (<http://geneticassociationdb.nih.gov/>)). RV infection inhibited many important biological processes in the host cell, including posttranslational protein modification, ubiquitin cycle, intracellular transport, and mRNA processing (Table 4). Of the 42 genes that were differentially expressed in the asthma vs. normal samples after RV infection, many were classified in the “defense response” and “cell–cell signaling” functional categories.

Analysis of the same data set using Gene Set Enrichment Analysis (GSEA, Broad Institute, Cambridge, MA) software revealed that RV infection of both groups upregulated genes classified in NF κ B, TNF, and double-stranded RNA (poly I:C) pathways. Downregulated genes were related to metabolic pathways for pyruvate, propanoate, and steroid biosynthesis, and to the Krebs–TCA cycle. Group-specific differences in gene expression patterns after RV infection were found in “local acute inflammatory response” and “genes upregulated by NF κ B” categories. Overall, both functional classification approaches revealed similar findings.

PCR validation of microarray results

To test the validity of the microarray data, additional samples of cells from normal and asthmatic volunteers were grown, and host cell mRNA was analyzed by quantitative PCR. These additional experiments confirmed virus induction of seven common upregulated genes, both in normal and asthmatic samples (Figure 3).

Of the mRNAs that appeared to be more highly expressed in asthma by microarray, similar patterns of expression were identified for several genes by qPCR (Figure 4). Notably, both *INHBA* and intercellular adhesion molecule 1 (*ICAM1*) tended to be expressed at higher levels in the uninfected asthma samples ($P < 0.1$), and similar differences were present in infected samples. In contrast, *LOXL2* was expressed at higher levels in the asthma samples ($P < 0.05$), and was downregulated by human RV in both groups. Similar nonsignificant patterns were observed for fibronectin 1 (*FNI*); ADAM metallopeptidase domain 19 (*ADAM19*); and secreted protein, acidic, cysteine-rich (*SPARC*). *IFI44* tended to be more upregulated in normal samples after infection. Finally, *IL1F9* had similar baseline expression in the two groups, but was more highly induced by RV infection in the asthma group ($P < 0.05$), and similar nonsignificant patterns were noted for *CSF3*, *IL6*, and *IL24*.

The microarray analysis identified increased expression of *IL28A*, but not of *IFNB1*, mRNA after RV infection, despite the availability of the corresponding probes in genechips. In the validation experiments using qPCR, both *IFNB1* and *IL28* mRNAs were upregulated after infection of both normal (7.5-fold ($P = 0.01$) and 6.3-fold ($P = 0.04$), respectively) and asthmatic (8.2-fold ($P < 0.01$) and 5.9-fold ($P = 0.03$), respectively) cells. *IL29* gene was also upregulated after infection, but its very low expression levels were not sufficient for reliable comparisons. There were no significant group-specific differences in RV-induced IFN mRNA expression.

Virus infection induces expression of inflammatory cytokines *in vitro*

Reagents were available for a subset of differentially expressed genes to test for group-specific differences in RV-induced protein expression. We quantified protein expression of three secreted proinflammatory cytokines, IL1B, IL6, and IL8, in cell culture media of RV-infected and control samples. Virus infection increased protein levels of all three cytokines, both in normal and asthmatic samples ($P < 0.05$), 16 h p.i. (Figure 5). IL6 tended to be upregulated in asthma samples with or without infection, but there were no significant differences between groups.

DISCUSSION

Genome-wide transcriptional analysis was employed to determine whether asthma is associated with a unique pattern of epithelial cell gene expression after RV infection. RV1A induced characteristic cytopathic effect and efficiently replicated in PBE cell monolayers, producing similar amounts of viral RNA in cells from donors with vs. without asthma. The transcriptional response to RV infection, characterized by robust upregulation of proinflammatory pathways and downregulation of cell metabolic processes, was also similar in normal and asthmatic cells. However, both paired (infected vs. mock) and unpaired (asthma vs. normal) comparisons revealed sets of differentially expressed genes related to inflammatory mechanisms and epithelial repair that clearly separated the asthma and normal groups by hierarchical clustering. Notably, most genes that were differentially expressed in the asthma group after RV infection were also differentially expressed in uninfected cells.

Different technical approaches can be used to study responses to viral infection *in vitro*. We chose to use the undifferentiated cell culture model that has the advantage of allowing analysis of cells that are fairly uniform in their susceptibility to infection. Air–liquid interface cultures of the well-differentiated cells are more resistant to RV infection with a relatively small proportion of infected cells (~5%).^{5,10,11} Therefore, the transcriptional response to RV infection is measured primarily in uninfected cells. In our system, the much higher rate of cellular infection may account for the fact that RV infection inhibits global host transcription and induces relatively few antiviral genes.^{12,13}

Recent studies using cultured PBE monolayers showed increased (≥ 10 -fold) RV replication in cell monolayers obtained from subjects with atopic asthma, whereas cells from normal




Figure 2 Patterns of gene expression in normal and asthmatic cells. **(a)** Area-proportional Venn diagrams showing up- and downregulated genes determined in asthma and normal group samples after rhinovirus (RV) infection. Changes in gene expression (greater than or equal to twofold, adjusted $P < 0.05$) common to both groups are shown by overlapping areas. The diagrams were generated with an online tool available at <http://www.venndiagram.tk/>. **(b)** Clustering analysis of gene expression patterns. Genes ($n = 42$) were selected based on differential expression in infected cells from asthma vs. normal group, and then expression intensity values of mock- and RV-infected samples were analyzed by hierarchical clustering of samples and genes. The gene expression patterns of asthma (A) and normal (N) samples clustered together for uninfected (M; mock), as well as RV-infected, cells. Clusters of asthma samples are shown in blue. Color bar represents fold changes (log₂ scale) in expression for each gene compared with median. HRV, human RV.

Table 3 Differentially expressed genes: asthma vs. normal groups

Gene symbol	Gene name	Biological function	FD ^a	P-value ^b
Differentially expressed after RV infection				
<i>LOXL2</i>	Lysyl oxidase-like 2	Cross-linking of collagen and elastin	2.2	0.010
<i>MMP10</i>	Matrix metalloproteinase 10 (stromelysin 2)	Metalloproteinase	2.2	0.040
<i>C15orf48</i>	Chromosome 15 open reading frame 48	Tumor suppressor	2.2	0.008
<i>LOC401074</i>	Hypothetical LOC401074	NA	2.1	0.004
<i>CCDC58</i>	Coiled-coil domain containing 58	NA	2.1	0.010
<i>INHBA</i>	Inhibin, beta A	Growth/differentiation factor	2.1	0.045
<i>IL1F9</i>	Interleukin 1 family, member 9	Cytokine	2.0	0.004
<i>MSMB</i>	Microseminoprotein, beta	Tumor suppressor	-3.6	0.031
<i>IFI44</i>	Interferon-induced protein 44	Response to virus, cell-cycle arrest	-2.1	0.002
Differentially expressed in mock-infected cells				
<i>ADAM19</i>	ADAM metalloproteinase domain 19	Metalloproteinase, cell-matrix interactions	2.8	0.023
<i>SPARC</i>	Secreted protein, acidic, cysteine-rich (osteonectin)	Synthesis of ECM, changes in cell shape	2.6	0.034
<i>MAP1B^c</i>	Microtubule-associated protein 1B	Microtubule assembly	2.6	0.014
<i>LOC401074</i>	NA	NA	2.3	0.014
<i>227140_at^d</i>	NA	NA	2.3	0.038
<i>FN1</i>	Fibronectin 1	Cell adhesion and migration	2.3	0.050
<i>MAN1A1</i>	Mannosidase, alpha, class 1A, member 1	Glycosyl hydrolase	2.3	0.002
<i>AKAP12</i>	A kinase (PRKA) anchor protein 12	Scaffold protein, binds to protein kinase A	2.3	0.040
<i>CCDC58</i>	Coiled-coil domain containing 58	NA	2.2	0.014
<i>LOXL2</i>	Lysyl oxidase-like 2	Cross-linking of collagen and elastin	2.2	0.006
<i>CXCL5</i>	Chemokine (C-X-C motif) ligand 5	Neutrophil activation	2.2	0.046
<i>SCG5</i>	Secretogranin V (7B2 protein)	Calcium binding	2.1	0.039
<i>TMSB15</i>	Thymosin beta 15a	Metastasis of human prostate and breast cancer	2.1	0.015
<i>COL4A1^c</i>	Collagen, type IV, alpha 1	ECM structural protein	2.1	0.022
<i>IGF2BP3</i>	Insulin-like growth factor 2 mRNA-binding protein 3	RNA synthesis and metabolism	2.0	0.035
<i>SLC46A3</i>	Solute carrier family 46, member 3	Integral to membrane	2.0	0.031
<i>C15orf48</i>	Chromosome 15 open reading frame 48	Tumor suppressor	2.0	0.019
<i>SERPINE1^c</i>	Serpin peptidase inhibitor, clade E	Plasminogen activator inhibitor	2.0	0.035
<i>INHBA</i>	Inhibin, beta A	Growth/differentiation factor	1.9	0.028
<i>PPL</i>	Periplakin	Structural protein, desmosomes	-2.0	0.025
<i>MSMB^c</i>	Microseminoprotein, beta	Tumor suppressor	-2.6	0.014

ECM, extracellular matrix; FD, fold difference (in expression); NA, not available; RV, rhinovirus.

^aNegative numbers indicate downregulation in asthmatic cells compared with normal cells.

^bNominal *P*-values from unpaired *t*-test comparison of asthma vs. normal samples (either infected or mock-infected).

^cThese genes had more than one probe set that revealed similar expression changes; corresponding fold changes and *P*-values were averaged.

^dGene symbol is not available for the probe set.

volunteers were more resistant to infection.^{6,7} In contrast to these reports, but in a good agreement with the recent findings in differentiated PBE cell cultures,¹⁴ we found very similar amounts of viral RNA by qRT-PCR, both in supernatants, adherent cells and in total virus yields in cells from normal and asthmatic subjects. Mechanisms that have been proposed to explain enhanced RV replication in asthmatic cells in previous studies are deficient production of type I and III IFN, and impaired early induction of apoptosis. In our microarray analysis of RV1A

infection, we detected a 2.1-fold induction of the type III IFN mRNA (IL28A) after RV infection in normal cells, and somewhat less (1.6-fold, *P* = 0.115) in cells from the asthma group. Although IFNB1 expression was not detected by microarrays, we used more sensitive qPCR methodology to confirm induction of both IL28 and IFNB1 mRNAs. However, there were no significant differences in IFN expression related to asthma.

It is possible that the different findings were because of differences in experimental technique, virus strain, or subject

Table 4 Functional groupings of genes that are downregulated after RV infection or differentially expressed in asthma

DAVID functional group term	Gene number ^a	Genes ^b (%)	P-value ^c
Downregulated genes (975 genes)			
<i>Biological process (GO database)</i>			
Posttranslational protein modification	120	14	3×10 ⁻⁸
Biopolymer metabolic process	310	35	5×10 ⁻⁷
Intracellular transport	65	7	2×10 ⁻⁶
Ubiquitin cycle	50	6	1×10 ⁻⁵
Protein transport	58	7	9×10 ⁻⁵
mRNA processing	29	3	1×10 ⁻⁴
Differentially expressed in asthma compared with normal (42 genes)			
<i>Biological process (GO database)</i>			
Defense response	6	14	0.008
Cell-cell signaling	7	16	0.003
Response to external stimulus	7	16	0.002
Cell surface receptor-linked signal transduction	10	23	0.004
Immune response	7	16	0.003

DAVID, Database for Annotation, Visualization and Integrated Discovery; GO, Gene Ontology; RV, rhinovirus.

^aGenes involved in the term.

^bPercentage of involved genes from total gene list.

^cModified Fisher exact P-value.




Figure 3 Genes upregulated by rhinovirus (RV) infection: analysis by microarray vs. quantitative reverse transcription (qRT)-PCR. Seven target genes that were upregulated in both RV-infected normal (N) and asthma (A) samples by microarray were analyzed in separate experiments using qRT-PCR. Expression levels in RV-infected cells were compared with those in mock-infected cells. Expression profiles were determined in six normal and five asthma samples.

selection. All the subjects in our studies had mild persistent atopic asthma, and we are currently conducting studies with cells obtained from donors with a more severe disease. Interestingly, IFNB1 mRNA induction after RV16 infection was not detected in another study using similar Affymetrix arrays,⁵ indicating a possible problem with sensitivity of this probe set.

Rhinovirus, similar to several other picornaviruses, induces gene expression shutoff in host cells through activities of two viral proteinases, 2A^{Pro} and 3C^{Pro}, that cleave multiple translation and transcription factors, and nuclear pore complex

proteins.¹⁵ Accordingly, more than 90% of differentially expressed genes in our study were reduced in expression, and many of these genes are involved in cell metabolism pathways.

The most highly upregulated genes were enriched for inflammatory mechanisms, and many of the induced factors (e.g., CSF2, CSF3, IL6, IL8, and TNF) have been previously identified in experimental models and clinical infections^{3,4,16,17} and shown to have roles in airway inflammation.^{18–21} Additional inflammatory factors were also upregulated by infection, including cytokines (IL1F9 and IL24) and transcription factors that regulate inflammatory responses in airways (EGR1 and FOSL1).^{22–25} Notably, some of the upregulated cytokines and their receptors (e.g., TNF, CCL5, CSF2, and IL1RN), and inflammatory factors (SOCS1, PTGS2, serpin peptidase inhibitor B2 (SERPINB2), and EDN1) have been linked to asthma in genetic and microarray studies, and in mouse models of asthma.^{26–34}

The main goal of our study was to identify genes that were differentially expressed with RV infection in the asthma vs. normal cell groups. Two categories of factors were identified by the analysis and hierarchical clustering: (i) different expression levels at baseline and after infection (most common), and (ii) similar expression at baseline and different expression after infection. The first category included genes implicated in airway repair and remodeling (*INHBA*, *MMP10*, *LOXL2*, *FN1*, and *SPARC*), and interestingly, *ICAM1*, which is used as a receptor by major group RV. These findings provide evidence that epithelial cells from individuals with asthma may be fundamentally different at baseline in the absence of infection. There were relatively few genes that were differentially expressed in asthmatic cells after infection but not at baseline (*IL1F9*, *CSF3*, *IFI44*, and *IL24*). Notably, *IL1F9* is upregulated in PBE cells after microbial exposure,²² and *IL24* is the key cytokine to trigger the upregula-




Figure 4 Quantitative PCR analysis of genes differentially expressed in asthma. Genes that were induced ($n=8$) or inhibited ($n=4$) by rhinovirus (RV) infection, and also differentially expressed in asthma samples by microarray were analyzed in separate experiments using quantitative reverse transcription PCR. Expression values are $2^{-\Delta Ct}$ values determined by relative quantification method. Each line represents the mean and standard deviation. * $P < 0.05$; † $P < 0.1$. HRV, human RV.

tion of class I IFNs.³⁵ Additional clinical studies are required to determine whether these cytokines contribute to the increased morbidity of RV infections in patients with asthma.

One of the limitations of our study is that the differences in expression found between normal and asthmatic cells were not statistically significant after correcting for multiple comparisons, and we elected to test the validity of the microarray findings by conducting additional independent experiments that were analyzed by qRT-PCR. Overall, the two techniques showed very good correlation, both in terms of direction and magnitude of changes. Moreover, gene expression changes in six additional PBE cell cultures tested in preliminary studies using HG Focus

GeneChips were consistent with those discussed in this paper. In addition to mRNA expression, we confirmed that protein expression of three secreted cytokines (IL1B, IL6, and IL8) was induced in cell culture media after RV infection, consistent with microarray and qRT-PCR results. Owing to the limited number of replicates, it should be acknowledged that the chances of a type II statistical error are high, and there certainly could be small asthma-related differences in the RV-induced gene expression patterns that were not detected in our study.

In addition to confirmation of our findings by statistical and quantitative means, we compared them with those of other published studies involving microarray analysis. Gene expression




Figure 5 Expression of three secreted proinflammatory cytokines in cell culture supernatants. Three tested cytokines were significantly induced at 16 h after rhinovirus (RV) infection, both in normal and asthmatic primary bronchial epithelial (PBE) cells ($P < 0.05$); differences between asthma and normal groups were not significant ($P > 0.05$). Each line represents the mean and standard deviation. HRV, human RV.

profiles in nasal epithelial scrapings after experimental RV16 infection of normal volunteers have showed upregulation of chemokines, signaling molecules, IFN-responsive genes, and antivirals, and a number of these factors (*CCL20*, *SOCS1*, *SOCS3*, and *OASL*) were also identified in our study of isolated epithelial cells.³⁶ Microarrays have recently been used to analyze inflammatory responses in asthma after allergen challenge, neuropeptide stimulation, and corticosteroid resistance.^{37–39} In spite of significant differences between cell types and/or stimulus, we found overlap between RV-induced changes in gene expression, and those found in brushings of mild asthmatics after allergen challenge (*GOS2*, *IL1RN*, *IL1B*, *IL8*, *SERPINB2*, *MMP10*, and *SPARC*),³⁷ after neuropeptide stimulation of epithelial cells (*INHBA*, *MMP10*, *EGR1*, *SERPINB2*, *FOSL1*, *CXCL2*, *IL8*, and *PTGS2*),³⁸ and in bronchoalveolar lavage cells from subjects with corticosteroid-resistant asthma (*IL6*, *TNF*, *IL1B*, *CCL20*, *IL8*, *CXCL1*, *CXCL2*, *CXCL3*, *EGR1*, and *TNFAIP3*).³⁹ Taken together, these similarities at transcriptional level could show the existence of some common mechanisms of asthma.

Overall, we showed similar RV replication rates and transcriptional response to RV1A in normal and asthmatic PBE cells. These findings suggest that factors outside of the epithelial cell, such as airway inflammation and abnormal airway structure and physiology, are important contributors to more severe clinical outcomes of common cold infections in asthma. Even so, our studies identified a subset of epithelial cell genes that were differentially expressed in asthma compared with those in normal subjects with functions related to inflammatory pathways, and regulation of airway repair and extracellular matrix. Further characterization of these potential asthma-related differences in the epithelial cell response to viral infection should provide a better understanding of molecular mechanisms of virus-induced asthma exacerbations.

METHODS

Cell culture and viral infection. Human PBE cells were obtained from the bronchial brushings of normal and asthmatic individuals (Table 1). Subjects in the asthma group were required to have doctor-diagnosed

asthma, and either methacholine PC₂₀ (provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 sec (FEV1)) ≤ 8 mg ml⁻¹ or at least 12% reversibility in FEV1 after administration of albuterol. Prick skin testing was performed using a panel of 15 common allergens, including grass and tree pollens, dust, dog and cat hair, and a positive response was defined as a wheal size greater than the histamine-negative control. Cells were grown at 37 °C (5% CO₂) in bronchial epithelial growth medium (BEGM, Lonza, Walkersville, MD). Purified and concentrated RV1A was diluted in bronchial epithelial growth medium with a reduced concentration of hydrocortisone (10⁻⁸ M) just before infection. One six-well plate of PBE cells from each patient was either infected with RV1A (10 PFU per cell) or mock-infected with medium alone. At collection (16 h p.i.), cell monolayers were washed thrice with phosphate-buffered saline and lysed by adding TRIzol Reagent (Invitrogen, Carlsbad, CA). Supernatant and cell lysate samples were stored in microcentrifuge tubes at -80 °C until RNA isolation. Detailed information about the cell culture and infection procedures is provided in the **Supplementary Materials** online. Preliminary experiments to determine the optimal virus dose (MOI of 2, 10, and 50 PFU per cell) and time p.i. (8, 16, and 24 h) were conducted with PBE cells obtained by enzymatic digestion of bronchi from two lung transplants⁴⁰ and used at passages 2–3. Cells were grown in bronchial epithelial growth media and infected with RV1A as described above.

Optimization of RV infection procedure for microarray analysis. The minor group RV1A was chosen for this study because minor group viruses infect a much larger percentage of cultured epithelial cells compared with major group viruses,⁴⁰ and RV1A and RV16 strains have been shown to induce similar expression changes in host cells *in vitro*.⁵ We carried out preliminary experiments to establish the optimal infectious dose of the virus and time p.i. that is the most informative for microarray analysis. The major criterion was to have a productive infection with clear cytopathic effect in host cells, in parallel with sufficient total RNA yield and quality for use as starting material in GeneChip analysis. Previous studies from our laboratory using HG Focus array (Affymetrix) and cells from three normal subjects showed that the maximal gene expression changes were observed 16 h p.i., and the vast majority of mRNAs upregulated earlier (4 and 8 h p.i.) remained induced at later time points (unpublished data). We then used this time point to compare different virus doses of infection in PBE cells from two normal lung donors. Infection at MOI of 10 PFU per cell caused distinctive cytopathic effect with more than 50% of cells being rounded and detached, while producing sufficient amount of total RNA (≥ 10 μ g) from adherent cells suitable for GeneChip hybridization (**Supplementary Figure 2** online).

RNA extraction and microarray hybridization. Total RNA was isolated from the frozen TRIzol lysates according to manufacturer's protocol, and then purified by the RNeasy Mini Kit (Qiagen, Hilden, Germany). A total of 10 µg of purified total RNA samples were submitted to the University of Wisconsin–Madison Gene Expression Center (Madison, WI) for labeling and hybridization. Following all appropriate protocols and procedures for eukaryotic total RNA quality control, labeling, and fragmentation, the biotin-labeled cRNA samples were hybridized to either the Human Genome Focus GeneChip Array (samples 1–6) or Human Genome U133 Plus 2.0 GeneChip arrays (samples 7–18) (Affymetrix) according to the manufacturer's protocols.

Microarray data analysis. The CEL files extracted and processed with Affymetrix GeneChip Operating software (GCOS) were analyzed using Bioconductor⁴¹ package “affy” based on R 2.4.1 statistical software (www.r-project.org). Log₂-transformed expression values across all the chips were extracted using the Robust Multichip Average method.⁴² Processing with Robust Multichip Average method involved background correction, probe-level quantile normalization across all the chips, and expression summarization. Statistical analysis for detecting differentially expressed genes in two sample comparisons involved either a paired *t*-test or a two independent sample *t*-test. We used the Benjamini–Hochberg false discovery rate-controlling procedure to account for multiple testing.⁴³ Details are provided in the online supplement. Hierarchical clustering using centroid linkage method was performed on the basis of the selected gene sets using Cluster 3.0⁴⁴ (Human Genome Center, Institute of Medical Science, University of Tokyo, Japan) and visualized using JavaTreeView 1.1.1.⁴⁵ <http://jtreeview.sourceforge.net> The microarray data have been submitted to Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/projects/geo/>) and assigned the accession number GSE13396.

Functional analysis of differentially expressed genes. Annotation and functional clustering of selected probe sets were performed using the DAVID (National Cancer Institute at Frederick, Frederick, MD) web-accessible program.⁴⁶ Genes with multiple corresponding probe sets were analyzed only when all probe sets showed consistent changes in the same direction (up- or downregulation). The data were analyzed using the “Gene Functional Classification” tool using the “High” classification stringency setting.

In addition, pathway analysis was performed using Gene Set Enrichment Analysis (GSEA) software⁴⁷ that determines whether an *a priori* defined set of genes shows statistically significant differences between two biological states (e.g., mock and virus infection). We have performed GSEA on our pre-ranked list of genes for each comparison of interest. The genes were ranked on the basis of their *t*-test statistics, and GSEA was run in the weighted mode. The main feature of this type of analysis is that it can detect subtle changes present in the data set.

qRT-PCR validation of microarray results. First-strand cDNA synthesis was performed using the RT² First Strand Kit (SuperArray, Frederick, MD). Human RT² RNA QC PCR Array (SuperArray) was used to assess the quality and integrity of purified RNAs. A total of 11 selected genes differentially expressed in asthma were targeted using custom-designed RT² Profiler PCR Array (SuperArray). The list of target genes, amplicon size, and reference positions of SuperArray primers are shown in **Supplementary Table S5** online. Expression of 11 additional genes was tested using primers shown in **Supplementary Table S6** online. RT² Real-Time SYBR Green/ROX PCR master mix (SuperArray) was used to perform the reactions. Fold differences were determined by the 2^{-ΔΔC_t} method. RV RNA was quantified in supernatants and adherent cells after infection using the two primers and probes described previously.⁴⁸ Additional details on qRT-PCR are provided in the online supplement.

Protein analysis. Supernatants from RV- and mock-infected cell cultures were assayed for IL8, IL1B, and IL6 proteins. IL8 chemokine concentrations were determined by sandwich ELISA using anti-human

IL8 monoclonal antibody in combination with biotinylated polyclonal detection antibody and recombinant IL-8 protein as the standard (R&D systems, Minneapolis, MN). IL1B and IL6 cytokine levels were assessed using human IL1B and IL6 Beadmates assays (Millipore, Temecula, CA) according to the manufacturer's instructions. Luminex 100 (Luminex Corporation, Austin, TX) instrument was used to run plates and generate quantitative data. Sensitivity of the IL1B and IL6 assays for the protocol used was 8.2 pg ml⁻¹.

Statistical analysis. Student's *t*-test was used to determine the statistical significance of the 5 data. Significance was defined at *P* < 0.05. Statistic calculations were carried out by SigmaPlot 11.0 software (Systat Software, San Jose, CA).

SUPPLEMENTARY MATERIAL is linked to the online version of the paper at <http://www.nature.com/mi>

ACKNOWLEDGMENTS

We thank Dr Wai-Ming Lee for providing us the purified and concentrated human rhinovirus strain 1A, and Ms. Kathryn Schmit for her technical assistance with qRT-PCR testing. This work was supported by grants NIAID/NIH U19 AI070503-01, NHLBI/NIH P01 HL70831-01, and NHLBI R01HL080412 from the National Institutes of Health (Bethesda, MD).

DISCLOSURE

The authors declare no conflict of interest.

© 2010 Society for Mucosal Immunology

REFERENCES

1. Corne, J.M. *et al.* Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. *Lancet* **359**, 831–834 (2002).
2. van Eiden, L.J. *et al.* Enhanced severity of virus associated lower respiratory tract disease in asthma patients may not be associated with delayed viral clearance and increased viral load in the upper respiratory tract. *J. Clin. Virol.* **41**, 116–121 (2008).
3. Hansbro, N.G., Horvat, J.C., Wark, P.A. & Hansbro, P.M. Understanding the mechanisms of viral induced asthma: new therapeutic directions. *Pharmacol. Ther.* **117**, 313–353 (2008).
4. Kallal, L.E. & Lukacs, N.W. The role of chemokines in virus-associated asthma exacerbations. *Curr. Allergy Asthma Rep.* **8**, 443–450 (2008).
5. Chen, Y. *et al.* Rhinovirus induces airway epithelial gene expression through double-stranded RNA and IFN-dependent pathways. *Am. J. Respir. Cell Mol. Biol.* **34**, 192–203 (2006).
6. Wark, P.A. *et al.* Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J. Exp. Med.* **201**, 937–947 (2005).
7. Contoli, M. *et al.* Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat. Med.* **12**, 1023–1026 (2006).
8. Amineva, S.P., Aminev, A.G., Palmenberg, A.C. & Gern, J.E. Rhinovirus 3C protease precursors 3CD and 3CD' localize to the nuclei of infected cells. *J. Gen. Virol.* **85**, 2969–2979 (2004).
9. Gustin, K.E. & Sarnow, P. Inhibition of nuclear import and alteration of nuclear pore complex composition by rhinovirus. *J. Virol.* **76**, 8787–8796 (2002).
10. Lopez-Souza, N. *et al.* Resistance of differentiated human airway epithelium to infection by rhinovirus. *Am. J. Physiol. Lung Cell Mol. Physiol.* **286**, L373–L381 (2004).
11. Jakiela, B., Brockman-Schneider, R., Amineva, S., Lee, W.M. & Gern, J.E. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. *Am. J. Respir. Cell Mol. Biol.* **38**, 517–523 (2008).
12. Neznanov, N. *et al.* Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. *J. Biol. Chem.* **280**, 24153–24158 (2005).
13. Kotla, S., Peng, T., Bumgarner, R.E. & Gustin, K.E. Attenuation of the type I interferon response in cells infected with human rhinovirus. *Virology* **374**, 399–410 (2008).
14. Lopez-Souza, N. *et al.* *In vitro* susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. *J. Allergy Clin. Immunol.* **123**, 1384–1390 (2009).

15. Lyles, D.S. Cytopathogenesis and inhibition of host gene expression by RNA viruses. *Microbiol. Mol. Biol. Rev.* **64**, 709–724 (2000).
16. Newcomb, D.C. *et al.* Cooperative effects of rhinovirus and TNF- α on airway epithelial cell chemokine expression. *Am. J. Physiol Lung Cell Mol. Physiol.* **293**, L1021–L1028 (2007).
17. Gern, J.E., Vrtis, R., Grindle, K.A., Swenson, C. & Busse, W.W. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. *Am. J. Respir. Crit. Care Med.* **162**, 2226–2231 (2000).
18. Dodge, I.L., Carr, M.W., Cernadas, M. & Brenner, M.B. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. *J. Immunol.* **170**, 4457–4464 (2003).
19. Doganci, A. *et al.* The IL-6R α chain controls lung CD4⁺CD25⁺ Treg development and function during allergic airway inflammation *in vivo*. *J. Clin. Invest.* **115**, 313–325 (2005).
20. Cates, E.C. *et al.* Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. *J. Immunol.* **173**, 6384–6392 (2004).
21. Yamashita, N. *et al.* Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). *Cell Immunol.* **219**, 92–97 (2002).
22. Vos, J.B. *et al.* Transcriptional response of bronchial epithelial cells to *Pseudomonas aeruginosa*: identification of early mediators of host defense. *Physiol Genomics* **21**, 324–336 (2005).
23. Silverman, E.S. *et al.* The transcription factor early growth-response factor 1 modulates tumor necrosis factor- α , immunoglobulin E, and airway responsiveness in mice. *Am. J. Respir. Crit. Care Med.* **163**, 778–785 (2001).
24. Ingram, J.L. *et al.* Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts. *J. Immunol.* **177**, 4141–4148 (2006).
25. Adisheshaiah, P., Vaz, M., Machireddy, N., Kalvakolanu, D.V. & Reddy, S.P. A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. *J. Cell Physiol.* **216**, 405–412 (2008).
26. Szczeklik, W., Sanak, M. & Szczeklik, A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. *J. Allergy Clin. Immunol.* **114**, 248–253 (2004).
27. Buckova, D., Izakovicova, H.L. & Vacha, J. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. *Allergy* **57**, 446–448 (2002).
28. Zhu, G. *et al.* Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populations. *Genes Immun.* **9**, 23–29 (2008).
29. Woodruff, P.G. *et al.* Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. *Proc. Natl. Acad. Sci. USA* **104**, 15858–15863 (2007).
30. Ramadas, R.A. *et al.* IL-1 receptor antagonist as a positional candidate gene in a murine model of allergic asthma. *Immunogenetics* **58**, 851–855 (2006).
31. Kumar, A., Gupta, V., Changotra, H., Sarin, B.C. & Sehajpal, P.K. Tumor necrosis factor- α and transforming growth factor- β 1 polymorphisms in bronchial asthma. *Indian J. Med. Sci.* **62**, 323–330 (2008).
32. Kamali-Sarvestani, E., Ghayomi, M.A. & Nekoei, A. Association of TNF- α -308 G/A and IL-4-589 C/T gene promoter polymorphisms with asthma susceptibility in the south of Iran. *J. Investig. Allergol. Clin. Immunol.* **17**, 361–366 (2007).
33. Lachheb, J., Chelbi, H., Hamzaoui, K. & Hamzaoui, A. Association between RANTES polymorphisms and asthma severity among Tunisian children. *Hum. Immunol.* **68**, 675–680 (2007).
34. Harada, M. *et al.* Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. *Am. J. Respir. Cell Mol. Biol.* **36**, 491–496 (2007).
35. Ekmekcioglu, S., Mumm, J.B., Udtha, M., Chada, S. & Grimm, E.A. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. *Cytokine* **43**, 34–44 (2008).
36. Proud, D. *et al.* Gene expression profiles during *in vivo* human rhinovirus infection: insights into the host response. *Am. J. Respir. Crit. Care Med.* **178**, 962–968 (2008).
37. Lilly, C.M., Tateno, H., Oguma, T., Israel, E. & Sonna, L.A. Effects of allergen challenge on airway epithelial cell gene expression. *Am. J. Respir. Crit. Care Med.* **171**, 579–586 (2005).
38. Vendelin, J. *et al.* Downstream target genes of the neuropeptide S-NPSR1 pathway. *Hum. Mol. Genet.* **15**, 2923–2935 (2006).
39. Goleva, E. *et al.* Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. *J. Allergy Clin. Immunol.* **122**, 550–559 (2008).
40. Schroth, M.K. *et al.* Rhinovirus replication causes RANTES production in primary bronchial epithelial cells. *Am. J. Respir. Cell Mol. Biol.* **20**, 1220–1228 (1999).
41. Gentleman, R.C. *et al.* Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol.* **5**, R80 (2004).
42. Irizarry, R.A. *et al.* Summaries of Affymetrix GeneChip probe level data. *Nucleic Acids Res.* **31**, e15 (2003).
43. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Series B Stat. Methodol.* **57**, 289–300 (1995).
44. de Hoon, M.J., Imoto, S., Nolan, J. & Miyano, S. Open source clustering software. *Bioinformatics* **20**, 1453–1454 (2004).
45. Saldanha, A.J. Java Treeview—extensible visualization of microarray data. *Bioinformatics* **20**, 3246–3248 (2004).
46. Dennis, G. Jr. *et al.* DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol.* **4**, 3 (2003).
47. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550 (2005).
48. Mosser, A.G. *et al.* Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues. *Am. J. Respir. Crit. Care Med.* **171**, 645–651 (2005).